This study is for adults with non-small-cell lung cancer (NSCLC) that is hard to remove or has spread. The study compares two treatments: a new medicine called PF-08046054 and a standard one called docetaxel. NSCLC patients must have a protein called PD-L1. PD-L1 lets cancer hide from the immune system. To join, patients should have tried specific treatments and not gotten better. Participants are randomly chosen to get either the new medicine or docetaxel through an IV, which means the medicine goes straight into their veins. PF-08046054 is given twice every 21 days, while docetaxel is given once every 21 days. The study might last up to 5 years to see how well the treatment works. Regular clinic visits will check participants' progress.

• Study Duration: Up to 5 years.
• Visits: Regular visits for treatment and check-ups.
• Treatment: Randomly assigned to either PF-08046054 or docetaxel.